Marinus Pharmaceuticals Inc (MEX:MRNS)
MXN 124 0 (0%) Market Cap: 1.90 Bil Enterprise Value: 1.76 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 40/100

Marinus Pharmaceuticals, Inc. - Special Call Transcript

Sep 26, 2019 / 12:30PM GMT
Operator

Greetings. Welcome to Marinus Pharmaceuticals RSE Phase II Data Call. (Operator Instructions) Please note, this conference is being recorded. At this time, I will turn the conference over to Lisa Caperelli, Executive Director, Investor and Strategic Relations. Lisa, you may now begin.

Lisa M. Caperelli
Marinus Pharmaceuticals, Inc. - Executive Director of Investor & Strategic Relations

Thanks, Rob. Good morning, everyone, and thank you for joining this conference call, where we will review data from our Phase II clinical study evaluating intravenous ganaxolone in patients with refractory status epilepticus.

Participation on to -- participants on today's call are Dr. Scott Braunstein, CEO of Marinus; Dr. Lorianne Masuoka, our Chief Medical Officer; TJ Lyons, Vice President of Corporate and Business Development and Commercial Planning; and Dr. Henri Vaitkevicius, an investigator in this study. Available for the Q&A session will be Dr. Maciej Gasior, Executive Director of Clinical Development; and Edward Smith, our CFO.

Before we begin,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot